StockNews.com Initiates Coverage on Trinity Biotech (NASDAQ:TRIB)

StockNews.com began coverage on shares of Trinity Biotech (NASDAQ:TRIB) in a research note issued to investors on Wednesday. The brokerage issued a buy rating on the stock.

Trinity Biotech Stock Up 1.1 %

NASDAQ:TRIB opened at $1.85 on Wednesday. The company has a fifty day simple moving average of $2.04 and a two-hundred day simple moving average of $2.25. The company has a market cap of $14.10 million, a price-to-earnings ratio of -0.58 and a beta of 1.21. Trinity Biotech has a 52 week low of $1.79 and a 52 week high of $5.50.

Trinity Biotech (NASDAQ:TRIB) last posted its quarterly earnings results on Wednesday, January 31st. The company reported ($0.90) EPS for the quarter. The business had revenue of $14.68 million for the quarter. On average, analysts expect that Trinity Biotech will post -1.5 EPS for the current year.

About Trinity Biotech

Trinity Biotech plc acquires, together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.